1,969 reports of this reaction
3.4% of all PROPOFOL reports
#3 most reported adverse reaction
ANAPHYLACTIC SHOCK is the #3 most commonly reported adverse reaction for PROPOFOL, manufactured by Fresenius Kabi USA, LLC. There are 1,969 FDA adverse event reports linking PROPOFOL to ANAPHYLACTIC SHOCK. This represents approximately 3.4% of all 57,130 adverse event reports for this drug.
PROPOFOL has an overall safety score of 95 out of 100. Patients taking PROPOFOL who experience anaphylactic shock should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAPHYLACTIC SHOCK is moderately reported among PROPOFOL users, representing a notable but not dominant share of adverse events.
In addition to anaphylactic shock, the following adverse reactions have been reported for PROPOFOL:
The following drugs have also been linked to anaphylactic shock in FDA adverse event reports:
ANAPHYLACTIC SHOCK has been reported as an adverse event in 1,969 FDA reports for PROPOFOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAPHYLACTIC SHOCK accounts for approximately 3.4% of all adverse event reports for PROPOFOL, making it one of the most commonly reported side effect.
If you experience anaphylactic shock while taking PROPOFOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.